ERRATUM

Erratum to: The treatment with pasireotide in Cushing's disease: effects of long–term treatment on tumor mass in the experience of a single center

Chiara Simeoli[1] · Renata Simona Auriemma[2] · Fabio Tortora[3] · Monica De Leo[1] · Davide Iacuaniello[1] · Alessia Cozzolino[1] · Maria Cristina De Martino[1] · Claudia Pivonello[1] · Ciro Gabriele Mainolfi[4] · Riccardo Rossi[1] · Sossio Cirillo[3] · Annamaria Colao[1] · Rosario Pivonello[1]

**Erratum to: Endocrine (2015) 50:725–740
DOI 10.1007/s12020-015-0557-2**

In the original publication, some of the units in Tables 1, 2 and 3 are not correctly reported; in detail, throughout the text and tables, pituitary tumor volume is expressed in ml instead of mm^3. The corrected version of Tables 1, 2 and 3 are given below.

✉ Rosario Pivonello
rosario.pivonello@unina.it

[1] Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università ''Federico II'', Via Sergio Pansini 5, 80131 Naples, Italy

[2] Ios & Coleman Medicina Futura Medical Center, Naples, Italy

[3] Department of Internal and Experimental Medicine, Division of Neurological Sciences, Second University of Naples, Naples, Italy

[4] Dipartimento di Scienze Biomediche Avanzate, Università ''Federico II'', Naples, Italy

 Springer

Table 1 Patient's profile at study entry

Patients number	8
Patients Age (years)	38.9 ± 17.6
Microadenoma nr. (%)	7 (87.5)
Macroadenoma nr. (%)	1 (12.5)
Tumor volume (mm^3)	416.46 ± 937.07
UFC (nmol/24h)	771.75 ± 606.57
Median pasireotide starting dose (μg bid)	900

Table 2 Patient 1: Patient's profile before and after 3, 6, 12, 18, 21 and 24 months of pasireotide treatment

Parameters	Normal range	Baseline	3 months	6 months	Δ%[a]	12 months	Δ%[a]	18 months	21 months	24 months	Δ%[a]
Weight (kg)	–	104.5	95.5	89	−14.8	81.5	−22	83	82.1	81	−22.5
BMI (kg/m^2)	20–25	35.3	32.2	30	−15	27.5	−22.1	28	27.7	27.3	−22.7
Waist circumference (cm)	<88	119	112	103	−13.4	104	−12.6	98	103	97	−18.5
Ferriman–Gallwey score	<8	30	32	28	−6.7	23	−23.3	19	18	14	−53.3
HR QoL score	–	41	48	56	+36.6	50	+21.9	–	–	–	
BDI–II score	–	9	3	0	−100	1	−88.9	0	0	0	−100
SBP (mmHg)	<130	120	115	120	0	125	+4.2	130	120	112	−6.7
DBP (mmHg)	<85	70	70	80	+14.3	70	0	80	80	70	0
Fasting glucose (mmol/L)	3.9–6.9	6.3	5.7	5.1	−19	7.2	+14.3	6.1	6.5	6.1	−3.2
Insulin (mU/L)	3–25	81.6	21	83.3	+2.1	14.8	−81.9	24.4	14.6	40.3	−50.6
HBA1C (%)	3.5–6	5.5	–	6	+9.1	6.9	+25.4	6.6	6.9	7	+27.3
Total cholesterol (mmol/L)	2.2–5.2	5.3	4.8	4.9	−7.5	4.8	−9.4	4.8	5.1	4.8	−9.4
LDL cholesterol (mmol/L)	1.6–3.3	3.1	2.7	2.8	−9.7	2.9	−6.4	2.7	3	2.8	−9.7
HDL cholesterol (mmol/L)	>1.3	1.4	1.42	1.6	+14.3	1.5	+7.14	1.68	1.64	1.34	−4.3
Triglycerides (mmol/L)	0.3–1.7	3.7	3.4	2.5	−32.4	2.1	−43.2	2.1	2.3	3.3	−10.8
BMD lumbar vertebrae (mg/cm^3)	–	0.962	–	1.011	+5.1	1.002	+4.1	–	–	0.983	+2.2
BMD proximal femur total hip (mg/cm^3)	–	NP	–	1.012	–	NP	–	–	–	0.916	–
BMD proximal femur neck (mg/cm^3)	–	NP	–	0.972	–	0.838	–	–	–	0.856	–
Plasma ACTH (ng/L)	0–46	101	75	80	−20.8	82	−18.8	86	91	72	−28.7
Serum cortisol (nmol/L)	119–618	634	440	628	−0.95	574	−9.5	498	682	381	−39.9
Mean UFC (nmol/24 h)	30–145	535	132	138	−74.2	162	−69.7	127	145	111	−79.2
MRI: pituitary tumor diameters (mm)	–	15 × 21 × 17	–	11 × 15 × 12	–	10 × 12 × 8	–	–	–	9 × 12 × 8	–
MRI: pituitary tumor volume (mm^3)[b]	–	2731.05	–	1009.8	−63	489.6	−82	–	–	440.6	−84

BMI Body Mass Index, *HR QoL* Health–Related Quality of Life, *BDI–II* Beck Depression Inventory–II Questionnaire, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HbA1c* glycated haemoglobin, *BMD* bone mineral density, *UFC* urinary free cortisol, *MRI* magnetic resonance imaging, NP not performed

[a] vs baseline

[b] Tumor volume was calculated in line with the "Di Chiro & Nelson" formula (volume = height × length × width × π/6)

Table 3 Patient 2: Patient's profile before and after 3, 6, 12, 18, 21 and 24 months of pasireotide treatment

Parameters	Normal range	Baseline	3 months	6 months	Δ%[a]	12 months	Δ%[a]	18 months	21 months	24 months	Δ%[a]
Weight (kg)	–	61	60	56.5	−7.4	52.5	−13.9	55	56.7	56	−8.2
BMI (kg/m^2)	20–25	20.4	20	18.89	−7.4	17.55	−14	18.39	18.96	18.72	−8.2
Waist circumference (cm)	<88	80	80	84	+5	72	−10	75	75	73	−8.75
Ferriman–Gallwey score	<8	11	3	1	−90.9	1	−91	1	1	1	−90.9
HR QoL score	–	37	31	35	−5.4	41	+10.8	–	–	–	–
BDI–II score	–	21	23	20	−4.8	17	−19	12	8	6	−71.4
SBP (mmHg)	<130	110	100	102	−7.3	105	−4.5	110	100	100	−9.1
DBP (mmHg)	<85	70	70	60	−14.3	65	−7.1	70	70	60	−14.3
Fasting glucose (mmol/L)	3.9–6.9	4.1	4.1	4.3	+4.9	4.2	+2.4	4.7	3.9	4.3	+4.9
Insulin (mU/L)	3–25	21.3	7.7	5.9	−72.3	5.4	−74.6	4.8	16.1	5.4	−74.6
HBA1C (%)	3.5–6	5.4	–	5.6	+3.7	5.3	−1.85	5.6	5.7	5.8	+7.4
Total cholesterol (mmol/L)	2.2–5.2	5.4	4.8	4.2	−22.2	4.5	−16.7	5.1	5.6	5.4	0
LDL cholesterol (mmol/L)	1.6–3.3	2.6	2.5	2.1	−19.2	2.2	−15.4	2.6	2.7	2.9	+11.5
HDL cholesterol (mmol/L)	>1.3	2.64	2.12	1.98	−25	2.18	−17.4	2.34	2.76	2.36	−10.6
Triglycerides (mmol/L)	0.3−1.7	0.8	0.9	0.6	−25	0.6	−25	0.8	0.7	0.7	−12.5
BMD lumbar vertebrae (mg/cm^3)	–	0.822	–	0.815	−0.6	0.8	−2.4	–	–	0.769	−6.2
BMD proximal femur total hip (mg/cm^3)	–	0.656	–	0.647	−0.5	NP	–	–	–	0.669	+2.9
BMD proximal femur neck (mg/cm^3)	–	0.723	–	0.726	+0.4	0.473	−34.6	–	–	0.748	+3.45
Plasma ACTH (ng/L)	0–46	32	13	13	−59.4	22	−31.25	22	20	21	−34.4
Serum cortisol (nmol/L)	119–618	495	287	322	−34.9	512	+3.4	584	492	573	+15.7
Mean UFC (nmol/24 h)	30–145	580	20	48.5	−91.6	85.75	−85.2	88	182	221.5	−61.8
MRI: pituitary tumor diameters (mm)	–	6 × 7 × 6	–	2.5 × 2.8 × 3	–	0	–	–	–	0	–
MRI: pituitary tumor volume (mm^3)[b]	–	128.5	–	10.71	−91.7	0	−100	–	–	0	−100

BMI Body Mass Index, *HR QoL* Health–Related Quality of Life, *BDI–II* Beck Depression Inventory–II Questionnaire, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HbA1c* glycated haemoglobin, *BMD* bone mineral density, *UFC* urinary free cortisol, *MRI* magnetic resonance imaging, NP not performed

[a] vs baseline

[b] Tumor volume was calculated in line with the "Di Chiro & Nelson" formula (volume = height × length × width × π/6)